ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 74

Clinical Characteristics of Fibromyalgia in a Chronic Pain Population

Mark Gostine1, Fred Davis1, Bradley Roberts2, Rebecca Risko2, Joseph Cappelleri3, Michael Asmus4, Andrew Clair5 and Alesia Sadosky6, 1Michigan Pain Consultants, PC, Grand Rapids, MI, 2ProCare Systems, Inc., Grand Rapids, MI, 3Biostatistics, Pfizer, Inc., Groton, CT, 4North American Medical Affairs, Pfizer, Inc., Middleton, WI, 5Pfizer Inc., New York, NY, 6Pfizer Inc,, New York, NY

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: fibromyalgia and pain management

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The study’s purpose was to advance the understanding and treatment of fibromyalgia (FM) for patients in a chronic pain management center.  FM is a chronic disorder that causes widespread musculoskeletal pain and fatigue, as well as a number of other symptoms. FM pain ranges from mild to incapacitating.   Given the many possible co-morbidities associated with FM, we set out to examine clinical characteristics of FM patients compared with those with chronic pain but without FM.  We did this to identify and better match patients to appropriate therapy.

Methods: This was a retrospective study with a case-control design based on data collected from July 1999 to February 17, 2015 in multiple chronic pain clinics in the United States. Patients were assigned to the case group of FM patients based on specific inclusion criteria. Propensity-score 1:1 matching was used to match controls (non-malignant chronic pain patients without FM) to cases based on identified confounders.  A final sample of 1,070 controls and 1,069 cases was obtained to investigate co-morbidities, procedures, and regions of pain associated with FM.  Items from a pain health assessment were also used to investigate patient-reported measures such as impairment, pain, fatigue, and quality of sleep.  Pearson’s chi-square and odds ratios were used to assess the significance and magnitude of relationships, two-sample t-tests were used for patient procedures, and a mixed model with repeated measures was implemented for patient-reported outcomes.  Confidence intervals and effect sizes were included for each individual analysis.

Results: Nine additional International Classification of Diseases, Clinical Modification (ICD–9-CM) diagnoses were found to have odds ratios with large effect sizes (Cohen’s d > 0.8).  These diagnoses included chronic pain syndrome, latex allergy, muscle spasm, fasciitis, cervicalgia, thoracic pain, shoulder pain, rheumatoid arthritis, and cervical disorders (all p < 0.0001).  Six diagnoses were found to have a moderate effect size (Cohen’s d > 0.5): cystitis, cervical degeneration, anxiety, joint pain, lumbago, and cervical radiculitis.  Current Procedural Terminology (CPT) procedure codes for musculoskeletal pain, specifically, trigger point injections, were shown to be used to treat FM cases in 5.9 more instances than controls, on average.  There was insufficient evidence to suggest that patient-reported items from the pain health assessment were significantly different between cases and controls.

Conclusion: Multiple co-morbidities, diagnoses, and procedures were associated with FM patients in this study.  Pain management physicians are uniquely positioned to treat FM patients.  When coding procedural work they are driven by billing codes associated with each procedure and sometimes miss the fact they are dealing with a FM patient.  Our goal is develop an alert system of diagnoses and procedures that would help doctors in differentiating FM patients from other painful conditions.  Doing so is more practical and realistic than the current symptom severity scale and widespread pain index, both of which are rarely obtained in the pain management clinical setting.


Disclosure: M. Gostine, Pfizer, Inc. 235 E 42nd Street, New York, NY, 2; F. Davis, Pfizer, Inc., 235 E 42nd St., New York, NY, 2; B. Roberts, ProCare Systems, Inc., 3; R. Risko, ProCare Systems, Inc., 3; J. Cappelleri, Pfizer Inc, 3; M. Asmus, Pfizer, Inc., 235 E 42nd Street, New York, NY, 3; A. Clair, Pfizer Inc, 1,Pfizer Inc, 3; A. Sadosky, Pfizer Inc, 3,Pfizer Inc, 1.

To cite this abstract in AMA style:

Gostine M, Davis F, Roberts B, Risko R, Cappelleri J, Asmus M, Clair A, Sadosky A. Clinical Characteristics of Fibromyalgia in a Chronic Pain Population [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/clinical-characteristics-of-fibromyalgia-in-a-chronic-pain-population/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-characteristics-of-fibromyalgia-in-a-chronic-pain-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology